Previous 10 | Next 10 |
AC Immune to Present at the Jefferies 2023 London Healthcare Conference Lausanne, Switzerland, November 7, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced that Company Man...
2023-11-03 07:13:15 ET More on AC Immune Seeking Alpha’s Quant Rating on AC Immune Historical earnings data for AC Immune Financial information for AC Immune For further details see: AC Immune GAAP EPS of -$0.18 misses by $0.20
HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
AC Immune Reports Third Quarter 2023 Financial Results and Provides a Corporate Update Results from amyloid plaque reduction analysis (Abeta-PET) after 6 months of treatment with ACI-24.060 in ABATE Phase 1b/2 study on track for H1 2024 ACI-24.060 ABATE interim safety and immunogenici...
AC Immune to Host KOL Webinar on Amyloid Plaque PET Imaging in Alzheimer’s Disease as a Surrogate of Clinical Efficacy on November 9, 2023 Lausanne, Switzerland, November 02, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering pre...
FNCB Bancorp Inc. (FNCB) is expected to report for Q1 2024 Civista Bancshares Inc. (CIVB) is expected to report $0.6 for Q3 2023 ASLAN Pharmaceuticals Limited (ASLN) is expected to report $-0.85 for Q3 2023 Grupo Televisa S.A. (TV) is expected to report $0.02 for Q3 2023 Red River...
PRESS RELEASE AC Immune Clinical Data Published in Nature Communications Show Alpha-Synuclein PET Tracer ACI-12589 Has Potential as Neurodegenerative Disease Diagnostic ACI-12589 1 delivers the first element of a precision medicine approach by enabling early an...
AC Immune SA (ACIU) is expected to report $0 for Q3 2023
AC Immune Announces Upcoming Presentations at the 16 th CTAD Conference Lausanne, Switzerland, October 17, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today announced upco...
2023-10-10 08:51:03 ET SMX (Security Matters) ( SMX ) +109% Secures Majority Stake in True Gold Consortium. Mobilicom Limited ( MOB ) +47% . AC Immune ( ACIU ) +15% . Immunic ( IMUX ) +14% jumps after the bell on positive int...
News, Short Squeeze, Breakout and More Instantly...
AC Immune SA Company Name:
ACIU Stock Symbol:
NASDAQ Market:
2024-05-30 18:30:02 ET BTIG analyst issues BUY recommendation for ACIU on May 30, 2024 04:49PM ET. ACIU was trading at $3.97 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 1 - Buy recommendations . ...
2024-05-30 18:00:07 ET Thomas Shrader from BTIG issued a price target of $8.00 for ACIU on 2024-05-30 16:49:00. The adjusted price target was set to $8.00. At the time of the announcement, ACIU was trading at $3.97. The overall price target consensus is at $10.00 with hi...
AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering the development of precision medicine approaches for the diagnosis, treatment, ...